UCB accelerates ambitions in gene therapy with two deals

Belgian drugmaker UCB (Euronext: UCB) has announced the acquisition of Handl Therapeutics along with a new collaboration with Lacerta Therapeutics.

Both of the firms are gene therapy companies and the deals are evidence of UCB’s ambition in the space and its vision to move from symptomatic treatments to disease modification and eventually towards a cure.